

Performance of a Modified FilmArray® Respiratory Panel for Improved Detection of Respiratory Adenovirus Serotypes

Beth Lingenfelter, Kristen Kanack, Elizabeth Amioff, Kevin Bourzac, Whitney Ramos-Jensen, Matthew Jones, Maggie Buccambuso, Laura O'Connor, Brent Bishop, Samuel Richards, Shane Woodhouse, Jennifer Hoge, Ranae Lems, Tyler Healy, and Richard Ajioka
BioFire Diagnostics, Inc., Salt Lake City, UT

INTRODUCTION/BACKGROUND

Rapid and reliable detection of respiratory pathogens is a critical step in the diagnosis and treatment of respiratory infections. The FilmArray Respiratory Panel (RP) is a user-friendly, highly multiplexed in vitro diagnostic test for the detection of twenty different agents of upper respiratory tract infection from a nasopharyngeal swab (NPS) specimen in about an hour.

One of the 17 viral targets of the FilmArray RP test is Adenovirus. *Adenoviridae* is a genetically diverse family of viruses. Human adenoviruses (AdV) are classified into 7 species (A-G) and further distinguished into over 50 distinct serotypes. Adenovirus species B, C, and E are associated with respiratory illness, while infection with other species (A, D, F and G) typically leads to conjunctivitis or gastroenteritis. The Adenovirus assay in the FilmArray RP will detect many, but not all Adenovirus species and serotypes. The original FDA-cleared FilmArray RP was labeled with a limitation on the detection of AdV2 (C2) and AdV6 (C6) serotypes and the sensitivity for detection of several other respiratory AdV serotypes was reported to be lower than some published or commercial molecular adenovirus assays.

The FilmArray RP has recently been modified to improve detection of all respiratory adenovirus serotypes from NPS specimens. The performance of the modified panel was validated with analytical and clinical studies. Analytical studies were performed to characterize the sensitivity (limit of detection), reactivity (inclusivity) and specificity (cross-reactivity and performance in the presence of co-infecting organisms) for adenovirus in the modified panel. In addition, a clinical method comparison study was performed in which 222 archived clinical NPS specimens and 44 contrived specimens were tested with both the modified and unmodified FilmArray RP. Performance was compared for detection of AdV and all analytes on the panel. These studies validate that detection of all respiratory AdV serotypes, including C2 and C6, is improved with the modified FilmArray RP; while the performance of all other panel assays is unchanged compared to the original version of the test.

METHODS

Analytical studies were performed by spiking quantified viruses and/or bacteria into a simulated NPS sample matrix (human epithelial cells in Remel M4 Viral Transport medium) followed by testing with the original and/or modified FilmArray RP test.

The clinical comparison study was performed by testing 222 archived NPS specimens and 44 contrived NPS specimens with both original and modified FilmArray RP versions. Archived specimens were acquired from multiple source laboratories across the U.S. and Scotland and chosen based upon previous positive test results (from various tests including culture, DFA, lab developed PCR tests, or original FilmArray RP) to cover all analytes in the panel. Any specimen positive for Adenovirus by original or modified FilmArray RP was subject to bi-directional sequencing (hexon gene target) to determine the serotype of the virus. To supplement the archived specimens, contrived specimens were prepared by spiking *Chlamydomonas pneumoniae*, *Mycoplasma pneumoniae*, or Adenovirus serotypes C2 and C6 into archived NPS specimens. Operators performing the FilmArray RP testing were blinded to previous test results and contrived spiking scheme.

Modified FilmArray RP Can Detect Adenovirus and other Analytes in the Presence of Potentially Competing FilmArray RP Viruses (Co-Infection)

| Low Concentration Virus (LoD) | High Concentration Virus (~105 TCID ₅₀ /mL) | Modified RP Results |
|-------------------------------|--|--|
| AdV1 | HRV | Adenovirus Human Rhinovirus/Enterovirus |
| HRV | AdV1 | Human Rhinovirus/Enterovirus Adenovirus |
| AdV5 | hMPV | Human Metapneumovirus Adenovirus |
| hMPV | AdV5 | Human Metapneumovirus Adenovirus |
| AdV6 | RSV | Respiratory Syncytial Virus Adenovirus |
| RSV | AdV6 | Respiratory Syncytial Virus Adenovirus |
| AdV7 | AdV4 | Adenovirus |
| AdV4 | AdV7 | Adenovirus |
| AdV2 | AdV21 | Adenovirus |
| AdV21 | AdV2 | Adenovirus |

Contrived samples were prepared, each containing one FilmArray RP analyte at LoD concentration and another analyte at a high, potentially competitive, concentration (~10³ – 10⁵ TCID₅₀/mL). Samples were tested with the modified FilmArray RP and all spiked analytes were detected.

Analytical Sensitivity (Limit of Detection): Adenovirus Detection is Improved in Modified FilmArray RP as Compared to Original FilmArray RP

| Adenovirus Serotype | Concentration Detected by Original RP (TCID ₅₀ /mL) | Modified RP Limit of Detection* (TCID ₅₀ /mL) | Fold Improvement in Detection with Modified RP |
|---------------------|--|--|--|
| AdV1 (C1) | 300 | 100 | 3x |
| AdV2 (C2) | 30,000 | 100 | 300x |
| AdV6 (C6) | 3,000,000 | 100 | 30,000x |
| AdV4 (E4) | 300 | 100 | 3x |

* LoD confirmed by detection of Adenovirus in 20/20 (100%) of spiked samples at the indicated concentration

Contrived specimens were created by spiking respiratory serotypes of adenovirus (AdV1, AdV2, AdV6 and AdV4) into simulated NPS specimens at a concentration of 100 TCID₅₀/mL. Twenty replicate specimens were tested to confirm 100 TCID₅₀/mL as the Adenovirus Limit of Detection (LoD) for the modified FilmArray RP (Adenovirus detected in at least 19/20 replicates). LoD of the modified panel was compared to the concentration of each serotype previously detected by the original FilmArray RP to determine the fold improvement in detection.


Modified FilmArray RP has Improved Adenovirus C2 and C6 Detection as Compared to Original FilmArray RP

| Spike Level | # of Specimens Spiked | Detected by Original FilmArray RP | Detected by Modified FilmArray RP |
|--|-----------------------|-----------------------------------|-----------------------------------|
| Adenovirus C6 | | | |
| 12 TCID ₅₀ /mL (0.12 × LoD) | 1 | 0/1 (0%) | 1/1 (100%) |
| 120 TCID ₅₀ /mL (1.2 × LoD) | 2 | 0/2 (0%) | 2/2 (100%) |
| 1200 TCID ₅₀ /mL (12 × LoD) | 5 | 0/5 (0%) | 5/5 (100%) |
| 12000 TCID ₅₀ /mL (120 × LoD) | 2 | 0/2 (0%) | 2/2 (100%) |
| Total Adenovirus C6 | 10 | 0/10 (0%) | 10/10 (100%) |
| Adenovirus C2 | | | |
| 12 TCID ₅₀ /mL (0.12 × LoD) | 1 | 0/1 (0%) | 1/1 (100%) |
| 120 TCID ₅₀ /mL (1.2 × LoD) | 2 | 0/2 (0%) | 2/2 (100%) |
| 1200 TCID ₅₀ /mL (12 × LoD) | 5 | 0/5 (0%) | 5/5 (100%) |
| 12000 TCID ₅₀ /mL (120 × LoD) | 2 | 0/2 (0%) | 2/2 (100%) |
| Total Adenovirus C2 | 10 | 0/10 (0%) | 10/10 (100%) |

Contrived specimens were created by spiking Adenovirus C2 or C6 into archived NPS specimens at concentrations ranging from 12 to 12,000 TCID₅₀/mL (0.12 – 120 × LoD). Modified FilmArray RP detected Adenovirus in all 20 specimens; original FilmArray RP failed to detect Adenovirus in all of the contrived specimens.

Clinical Sensitivity: Modified FilmArray RP Detects Adenovirus in More Specimens than Original FilmArray RP Testing of 222 Archived Clinical NPS Specimens

Modified FilmArray RP = 26 Detected*




Original FilmArray RP detected Adenovirus in 15 of 222 archived NPS specimens. Modified FilmArray RP detected Adenovirus in the same 15 specimens and also detected Adenovirus in 11 additional specimens (26 total Adenovirus detections by modified FilmArray RP; 26/15 = 173% relative detection in this specimen set). Bi-directional sequencing was able to determine the serotype of Adenovirus in 24 specimens. Modified FilmArray RP demonstrated improved detection of C2, C5, C6, and E4 serotypes in archived clinical NPS specimens.

* The presence of adenovirus in all 26 specimens was confirmed by bi-directional sequence analysis.

| Adenovirus Subtype | Modified FilmArray RP # Detected | Original FilmArray RP Detections |
|-----------------------|--|---|
| AdV1 (C1) | 8 | 100% (8/8) |
| AdV2 (C2) | 4 | 50% (2/4) |
| AdV5 (C5) | 2 | 50% (1/2) |
| AdV6 (C6) | 6 | 17% (1/6) |
| AdV3 (B3) | 1 | 100% (1/1) |
| AdV4 (C4) | 3 | 67% (2/3) |
| AdV4 serotype unknown | 2 | 0% (0/2) |
| Total | 26 (26/15 = 173% of Original FilmArray RP) | 15 (15/26 = 58% of Modified FilmArray RP) |

Non-Adenovirus Analyte Performance is Equivalent in Original and Modified FilmArray RP


Detection of Non-Adenovirus Analytes is Equivalent between the Original and Modified FilmArray RP at LoD Levels



Five replicates of contrived samples spiked with each FilmArray RP analyte at its respective LoD concentration were tested with both the original and modified FilmArray RP and results were compared. Detection of each non-adenovirus FilmArray RP analyte at LoD concentration was as expected (at least 4/5 detected) and equivalent between the original and modified versions of the panel.

Detection of all non-Adenovirus analytes by modified FilmArray RP was compared to detection by original FilmArray RP when testing 222 archived specimens and 44 contrived specimens. Positive percent agreement (PPA) was 100% for the majority of analytes. A single discrepancy was observed for CoV NL63 (15/16; 93.8%), *B. pertussis* (25/26; 96.2%), and *C. pneumoniae* (8/9; 88.9% in contrived specimens). Four discrepancies were observed for Rhinovirus/Enterovirus (57/61; 93.4%). Negative Percent Agreement (NPA) was 98% or higher for all analytes.

Detection of Non-Adenovirus Analytes in Clinical NPS Specimens is Equivalent in Original and Modified FilmArray RP



| Analyte | RSV | PIV1 | PIV2 | PIV3 | PIV4 | <i>B. pert</i> | <i>Cpne</i> | <i>Cpne</i> Contrived | <i>Mpne</i> | <i>Mpne</i> Contrived |
|--------------------|----------------|----------------|----------------|----------------|----------------|-----------------|----------------|-----------------------|----------------|-----------------------|
| Positive Agreement | 100% (21/21) | 100% (11/11) | 100% (8/8) | 100% (18/18) | 100% (6/6) | 96.2% (25/26) | 100% (1/1) | 88.9% (8/9) | n/a (0/0) | 100% (14/14) |
| Negative Agreement | 100% (201/201) | 100% (211/211) | 100% (214/214) | 100% (204/204) | 100% (214/216) | 99.1% (196/196) | 100% (221/221) | 100% (35/35) | 100% (222/222) | 100% (30/30) |

| Analyte | CoV 229E | CoV HKU1 | CoV NL63 | CoV OC43 | hMPV | HRV/EV | FluA | FluA H1 | FluA H1 2009 | FluA H3 | FluB |
|--------------------|----------------|----------------|----------------|-----------------|-----------------|-----------------|-----------------|----------------|-----------------|----------------|----------------|
| Positive Agreement | 100% (6/6) | 100% (8/8) | 93.8% (15/16) | 100% (13/13) | 100% (10/10) | 93.4% (57/61) | 100% (36/36) | 100% (9/9) | 100% (15/15) | 100% (13/13) | 100% (10/10) |
| Negative Agreement | 100% (216/216) | 100% (214/214) | 100% (206/206) | 99.5% (208/209) | 98.6% (209/212) | 98.1% (158/161) | 99.5% (184/185) | 100% (213/213) | 99.5% (205/206) | 100% (209/209) | 100% (212/212) |

Analytical Reactivity (Inclusivity): Modified FilmArray RP Detects More Adenovirus Serotypes at Lower Concentrations as Compared to Original FilmArray RP

Modified FilmArray RP is More Inclusive for Adenovirus Respiratory Serotypes (Species B, C and E) Compared to Original FilmArray RP

| Species | Serotype | Isolate | Test Level TCID ₅₀ /mL | x LoD | Original RP | Modified RP |
|--------------|----------|---------------------|-----------------------------------|-------|-------------|-------------|
| B | AdV3 | Zepto #0810062CF | 100 | 1x | D | D |
| | AdV7a | Zepto #0810021CF | 100 | 1x | D | D |
| | AdV7d2 | Iowa/2001 | 100 | 1x | D | D |
| | AdV7h | Iowa/1999 | 100 | 1x | D | D |
| | AdV11 | Wisconsin/2005 | 100 | 1x | ND | D |
| | AdV14 | Missouri/2005 | 100 | 1x | ND | D |
| | AdV16 | ATCC VR-17 | 100 | 1x | D | D |
| | AdV21 | Missouri/2005 | 100 | 1x | ND | D |
| | AdV34 | UIRF-Texas/2005 | 100 | 1x | ND | D |
| | AdV35 | ATCC VR-718 | 100 | 1x | ND | D |
| C | AdV1 | Zepto#0810050CF | 100 | 1x | D | D |
| | AdV2 | New York/2004 | 100 | 1x | ND | D |
| | | ATCC VR-846 | 100 | 1x | ND | D |
| | AdV5 | Zepto#0810020CF | 100 | 1x | ND | D |
| | | Colorado/2005 | 100 | 1x | ND | D |
| | AdV6 | ATCC VR-6 | 100 | 1x | ND | D |
| ATCC VR-1602 | | 100 | 1x | ND | D | |
| E | AdV4a | South Carolina/2004 | 100 | 1x | D | D |
| | AdV4p3 | New Jersey/2005 | 100 | 1x | D | D |

Detection of Non-Respiratory Adenovirus Serotypes (Species A, D and F) Is Variable with Both the Original and Modified FilmArray RP

| Species | Serotype | Isolate | Test Level TCID ₅₀ /mL | x LoD | Original RP | Modified RP |
|---------|----------|-----------------|-----------------------------------|-------|-------------|-------------|
| A | AdV12 | ATCC VR-863 | 1,000 | 10x | ND | ND |
| | AdV18 | ATCC VR-19 | 1,000 | 10x | ND | ND |
| | AdV31 | Zepto#0810073CF | 1,000 | 10x | D | D |
| D | AdV8 | Zepto#0810069CF | 100 | 1x | ND | D |
| | AdV20 | Zepto#0810115CF | 100 | 1x | D | D |
| | AdV37 | Zepto#0810119CF | 100 | 1x | D | D |
| F | AdV40 | Zepto#0810084CF | 1,000 | 10x | ND | ND |
| | AdV41 | Indiana/2004 | 100 | 1x | D | D |

Representative isolates of 17 different AdV respiratory serotypes (species B, C, and E) and 8 different non-respiratory serotypes (species A, D and F) were spiked into simulated NPS sample matrix at a concentration of 100 TCID₅₀/mL and tested with both the original and modified FilmArray RP. All respiratory serotypes were detected (D) at this concentration (1 × LoD) by the modified panel, while several were not detected (ND) by the original panel. Non-respiratory serotypes that were not detected by either the modified or original panel were re-tested at a 10-fold higher concentration. If an isolate was not detected by either panel at 10 × LoD, no additional testing was performed.

SUMMARY

The modified FilmArray RP exhibited a 3-fold increase in analytical sensitivity (LoD) compared to the original panel and was shown to detect 17 different respiratory adenovirus serotypes within species B, C and E (including AdVC2 and AdVC6) at a concentration of 100 TCID₅₀/mL. No cross-reactivity with other respiratory pathogens was observed (data not shown) and the panel is able to accurately identify multiple pathogens from a single sample. In the clinical study, the modified FilmArray RP detected Adenovirus in 73% more archived specimens than the unmodified test (26 vs. 15 specimens respectively). Improved detection was observed for Adenovirus serotypes AdVC2, AdVC5, AdVC6, and AdVE4. The archived specimen testing data also demonstrate equivalent performance between the two test versions for all other analytes with Positive Percent Agreement of 93.4 – 100% and Negative Percent Agreement of 97.9 – 100%.

These data validate that the modified FilmArray RP, which recently received FDA clearance, has increased sensitivity for several Adenovirus serotypes and is capable of detecting more Adenoviruses in clinical specimens than the original version of the test.

ACKNOWLEDGEMENTS

Development of the FilmArray system was funded in part by NIH/NIAD grants 1R43 AI063695, U01 AI061611, and U01 AI074419. This study was funded by the Defense Threat Reduction Agency (HDTA1-09-C-0066).

CONTACT INFORMATION

Beth Lingenfelter
BioFire Diagnostics, Inc.
Beth.Lingenfelter@BioFireDX.com

